Posts

Posted on

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

New, improved formulation set to replace EGRIFTA SV®

MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection. The Company will commercialize the new formulation under the tradename EGRIFTA WR™.

Tesamorelin for injection is the only medication approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. The new formulation, EGRIFTA WR™, is a daily injectable but only needs weekly reconstitution. It requires less than half the administration volume as the current F4 formulation, sold in the U.S. as EGRIFTA SV®, which is reconstituted daily. Pharmacokinetic studies have shown bioequivalence of EGRIFTA WR™ to the original F1 formulation of tesamorelin for injection (previously sold under the trade name EGRIFTA®). The most commonly reported adverse reactions of EGRIFTA WR™ include arthralgia, injection site reactions, pain in extremity, peripheral edema, and myalgia.

“We are pleased to offer this improved, more convenient version of tesamorelin for injection to help people with HIV and their healthcare providers more effectively manage comorbidities like lipodystrophy, which today often presents as central adiposity,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. “EGRIFTA WR™ enables a simplified administration and an improved patient experience, which are important considerations for people living with HIV.”

EGRIFTA WR™ will be supplied as four single-patient-use vials, each containing 11.6 mg of tesamorelin, sufficient for seven doses. The daily dose is 1.28 mg (0.16 mL of the reconstituted solution) injected subcutaneously. The product can be stored at room temperature (20° to 25° C [68° to 77° F]) before and after reconstitution.

“Central adiposity, characterized by the accumulation of excess visceral abdominal fat (EVAF), is a common complication for people with HIV that may result from the virus itself, from certain older antiretrovirals and from a reduction in growth hormone concentrations,” commented David Alain Wohl, MD, Professor at the Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill. “Given the significant impact of EVAF on health and quality of life for many of our patients with HIV, and the importance of maintaining lean muscle mass especially as we age, a new, more conveniently dosed formulation of tesamorelin is a welcome advancement.”

EGRIFTA WR™ will be manufactured at a new, U.S.-based contract drug manufacturing organization (CDMO). The new formulation, which is patent protected in the U.S. until 2033, is set to replace EGRIFTA SV®.

Further information about EGRIFTA WR™, including full prescribing information, instructions for use, and important safety information is available here.

Important Safety Information

EGRIFTA WR™ (tesamorelin for injection) is approved in the U.S. for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy*. EGRIFTA WR™ is a growth hormone- releasing factor (GHRF) analog that acts on pituitary cells in the brain to stimulate the production and release of endogenous growth hormone.

Limitations of Use:

  • Long-term cardiovascular safety of EGRIFTA WR™ has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue.
  • EGRIFTA WR™ is not indicated for weight loss management as it has a weight- neutral effect.
  • There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA WR™.

Contraindications:

Do not use EGRIFTA WR™ if a patient:

  • Has disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma.
  • Has active cancer.
  • Is allergic to tesamorelin or any of the ingredients in EGRIFTA WR™.
  • Is pregnant or planning to become pregnant.

The most commonly reported adverse reactions of EGRIFTA WR™ include: arthralgia, injection site reactions, pain in extremity, peripheral edema, and myalgia.

Healthcare providers and patients are encouraged to report adverse events at 1-833-23THERA (1-833-238-4372). You are encouraged to report side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

Refer to this link for the full prescribing information, patient information and instructions for use for EGRIFTA WR™.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X.

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”) within the meaning of applicable securities laws, that are based on management’s beliefs and assumptions and on information currently available to it. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding: (i) the convenience of the F8 formulation; (ii) the experience of using the F8 formulation for patients; and (iii) the transition to the F8 formulation from EGRIFTA SV®. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements contained in this press release. Certain assumptions made in preparing the Forward-Looking Statements include that: (i) the marketplace will accept this new formulation of EGRIFTA SV®; and (ii) the F8 formulation of tesamorelin for injection will be reimbursed by private and public payors. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to: (i) patients and physicians do not adopt the F8 formulation of tesamorelin for injection; (ii) the F8 formulation of tesamorelin for injection does not get reimbursement coverage from private and/or public payors; and (iii) the transition to the F8 formulation is delayed due to various matters, including delays associated with the availability of materials required to commercialize the F8 formulation. The Company refers current and potential investors to the “Risk Factors” section of the Company’s annual information form filed under Form 20-F dated February 26, 2025 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date.

The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contacts:

Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
[email protected]
1-514-336-7800

Investor Inquiries:
Joanne Choi
Senior Director, Investor Relations
[email protected]
1-551-261-0401



Posted on

United Rentals Selected as One of America’s Best-Managed Companies

United Rentals Selected as One of America’s Best-Managed Companies

Company Chosen in Annual Management Top 250 List Presented by Wall Street Journal

STAMFORD, Conn.–(BUSINESS WIRE)–
United Rentals, Inc. (NYSE: URI), the world’s largest equipment rental company, today announced it was named to The 250 Best-Managed Companies list by the Wall Street Journal. The ranking was developed by the Drucker Institute based on its holistic model for measuring corporate management effectiveness, which reviews performance across key business drivers.

The 250 Best-Managed Companies list, published annually since 2017, is one of the industry’s most prestigious corporate management awards. To determine the rankings, the Drucker Institute evaluated U.S. publicly traded companies on 35 corporate performance indicators using data inputs from third-party providers. The research included a new metric of a “digital positioning score,” which looked at a company’s activity, as compared to industry peers, across online search, website traffic, social media and its apps.

“This recognition as an industry leader is a testament to the dedication and hard work of our team to be the best rental partner for our customers,” said Matthew Flannery, president and chief executive officer, United Rentals. “We have a relentless commitment to helping our customers safely build a better and stronger future, while also providing long-term value for all of our stakeholders.”

Information on career opportunities can be found on the United Rentals Careers website.

About United Rentals

United Rentals, Inc. is the largest equipment rental company in the world. The company has an integrated network of 1,591 rental locations in North America, 39 in Europe, 37 in Australia and 19 in New Zealand. In North America, the company operates in 49 states and every Canadian province. The company’s approximately 27,900 employees serve construction and industrial customers, utilities, municipalities, homeowners and others. The company offers a fleet of equipment for rent with a total original cost of $21.43 billion. United Rentals is a member of the Standard & Poor’s 500 Index, the Barron’s 400 Index and the Russell 3000 Index® and is headquartered in Stamford, Conn. Additional information about United Rentals is available at unitedrentals.com.

Elizabeth Grenfell

Vice President, Investor Relations

O: (203) 618-7125

[email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Transport Other Professional Services Human Resources Internet Landscape Building Systems Interior Design Other Construction & Property Architecture Professional Services Logistics/Supply Chain Management Residential Building & Real Estate Social Media Technology Commercial Building & Real Estate Construction & Property Communications Apps/Applications

MEDIA:

Posted on

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Perpetua Resources Corp. (PPTA)

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) — Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Idaho on behalf of all persons or entities who purchased or otherwise acquired Perpetua Resources Corp. (“Perpetua” or the “Company”) (NASDAQ: PPTA) securities between April 17, 2024 and February 13, 2025, inclusive (the “Class Period”).

The Complaint alleges that Defendants created the false impression that they possessed reliable information pertaining to the increase in initial capital expense for the Stibnite Gold Project while also minimizing the risk from the impact of inflation. In truth, Perpetua’s suggestion of a mere 10% to 20% increase in cost fell well short of reality; the true impact of inflation, increased costs, and, most importantly, decisions management made resulted in a drastic increase in the initial capital expenditure required for the Stibnite Gold Project.

The Complaint also alleges that on February 13, 2025, Perpetua published an updated cash flow model for the Stibnite Gold Project, unveiling additional capital expenses of $952 million, a more than 75% increase from the original figures presented to investors and well beyond the suggested 10-20% increase contemplated by Defendants. The Company attributed these increased costs on inflation, indirect costs, higher mining costs, and direct decisions Defendants made with respect to the project, including the choice to change the design of the electrical poles from timber to steel and the decision to “buy-and-build instead of lease the oxygen plant.” On this news, the price of the Company’s common stock declined from $11.97 per share on February 13, 2025, to $9.29 per share on February 14, 2025, a decline of about 22.39%.

Investors who purchased or otherwise acquired shares of Perpetua should contact the Firm prior to the May 20, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].

Please visit our website at http://www.gme-law.com for more information about the firm.



Posted on

EastGroup Properties Announces First Quarter 2025 Earnings Conference Call and Webcast

PR Newswire


JACKSON, Miss.
, March 25, 2025 /PRNewswire/ — EastGroup Properties, Inc. (NYSE: EGP) (the “Company” or “EastGroup”) announced today that it will hold its First Quarter 2025 Earnings Conference Call and Webcast on Thursday, April 24, 2025, at 11:00 a.m. Eastern Time.  On the call, Marshall Loeb, CEO, and Brent Wood, CFO, will discuss the Company’s first quarter results, current operations, and earnings outlook for 2025. 

EastGroup plans to release financial results for the quarter after the market closes on April 23, 2025. The earnings release and supplemental information package will be posted on the Company’s website, www.eastgroup.net, at that time.

A live broadcast of the conference call is available by dialing 1-800-836-8184 (conference ID EastGroup) or by webcast through a link on the Company’s website at www.eastgroup.net. If you are unable to listen to the live conference call, a telephone and webcast replay will be available on Thursday, April 24, 2025. The telephone replay will be available through Thursday, May 1, 2025, and can be accessed by dialing 1-888-660-6345 (access code 03256#). The replay of the webcast can be accessed through a link on the Company’s website at www.eastgroup.net and will be available through Thursday, May 1, 2025.


About EastGroup Properties, Inc.

EastGroup, a member of the S&P Mid-Cap 400 and Russell 2000 Indexes, is a self-administered equity real estate investment trust focused on the development, acquisition and operation of industrial properties in high-growth markets throughout the United States with an emphasis in the states of Texas, Florida, California, Arizona and North Carolina. The Company’s goal is to maximize shareholder value by being a leading provider in its markets of functional, flexible and quality business distribution space for location sensitive customers (primarily in the 20,000 to 100,000 square foot range). The Company’s strategy for growth is based on ownership of premier distribution facilities generally clustered near major transportation features in supply-constrained submarkets. EastGroup’s portfolio, including development projects and value-add acquisitions in lease-up and under construction, currently includes approximately 63.1 million square feet.

EastGroup Properties, Inc. press releases are available at www.eastgroup.net.

Contact: [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/eastgroup-properties-announces-first-quarter-2025-earnings-conference-call-and-webcast-302411317.html

SOURCE EastGroup Properties

Posted on

Starwood Property Trust Announces Upsizing and Pricing of Private Offering of Sustainability Bonds

PR Newswire


MIAMI BEACH, Fla.
, March 25, 2025 /PRNewswire/ — Starwood Property Trust, Inc. (NYSE: STWD) (the “Company”) today announced that it has priced its private offering of $500 million aggregate principal amount of its 6.500% unsecured senior notes due 2030 (the “Notes”), which was upsized from the previously announced $400 million aggregate principal amount. The Notes priced at 100.0% of the principal amount and the settlement of the offering is expected to occur on April 8, 2025, subject to customary closing conditions.

The Company intends to allocate an amount equal to the net proceeds from the offering to finance or refinance, in whole or in part, recently completed or future eligible green and/or social projects. Net proceeds allocated to previously incurred costs associated with eligible green and/or social projects will be available for the repayment of indebtedness previously incurred. Pending full allocation of an amount equal to the net proceeds to eligible green and/or social projects, the Company intends to use the net proceeds for general corporate purposes, which may include the repayment of outstanding indebtedness under the Company’s repurchase facilities.

The Notes were offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes will not initially be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of the Securities Act or any state securities laws.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Starwood Property Trust, Inc.

Starwood Property Trust, Inc. (NYSE: STWD), an affiliate of global private investment firm Starwood Capital Group, is a leading diversified finance company with a core focus on the real estate and infrastructure sectors. As of December 31, 2024, the Company has successfully deployed over $102 billion of capital since inception and manages a portfolio of $25 billion across debt and equity investments. Starwood Property Trust’s investment objective is to generate attractive and stable returns for shareholders, primarily through dividends, by leveraging a premiere global organization to identify and execute on the best risk adjusted returning investments across its target assets.

Forward-Looking Statements

Statements in this press release which are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to the anticipated settlement of the offering and the use of proceeds. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors that could cause actual results to differ materially from the Company’s expectations include: (i) factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, including those set forth under the captions “Risk Factors”, “Business”, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; (ii) defaults by borrowers in paying debt service on outstanding indebtedness; (iii) impairment in the value of real estate property securing the Company’s loans or in which the Company invests; (iv) availability of mortgage origination and acquisition opportunities acceptable to the Company; (v) potential mismatches in the timing of asset repayments and the maturity of the associated financing agreements; (vi) national and local economic and business conditions, including as a result of the impact of public health emergencies; (vii) the occurrence of certain geo-political events (such as wars, terrorist attacks and tensions between states, including global trade disputes related to tariffs) that affect the normal and peaceful course of international relations; (viii) general and local commercial and residential real estate property conditions; (ix) changes in federal government policies; (x) changes in federal, state and local governmental laws and regulations; (xi) increased competition from entities engaged in mortgage lending and securities investing activities; (xii) changes in interest rates; and (xiii) the availability of, and costs associated with, sources of liquidity.

Contact:

Zachary Tanenbaum

Starwood Property Trust
Phone: 203-422-7788
Email: [email protected]

Cision View original content:https://www.prnewswire.com/news-releases/starwood-property-trust-announces-upsizing-and-pricing-of-private-offering-of-sustainability-bonds-302411316.html

SOURCE Starwood Property Trust, Inc.

Posted on

Navigator Gas Announces Availability of its Annual Report on Form 20-F for the Year Ended December 31, 2024

LONDON, March 25, 2025 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, announces that it has filed its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission.

Form 20-F can be downloaded using the link below and is available on our website (www.navigatorgas.com) in the ‘Investors Centre’ section under ‘Financials’ then ‘SEC Filings’. Shareholders may request a hard copy at no cost using the contact details listed below.

2024 Form 20-F Annual Report

About Navigator Gas

Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) is the owner and operator of the world’s largest fleet of handysize liquefied gas carriers and a global leader in the seaborne transportation services of petrochemical gases, such as ethylene and ethane, liquefied petroleum gas (“LPG”) and ammonia and owns a 50% share, through a joint venture, in an ethylene export marine terminal at Morgan’s Point, Texas on the Houston Ship Channel, USA. Navigator Gas’ fleet consists of 59 semi- or fully-refrigerated liquefied gas carriers, 28 of which are ethylene and ethane capable. The Company plays a vital role in the liquefied gas supply chain for energy companies, industrial consumers and commodity traders, with its sophisticated vessels providing an efficient and reliable ‘floating pipeline’ between the parties, connecting the world today, creating a sustainable tomorrow.

Navigator Gas’ common stock trades on the New York Stock Exchange under the symbol “NVGS”.

For media enquiries or further information, please contact:

Alexander Walster
Head of ESG & Communications
Email: [email protected]
Verde, 10 Bressenden Place, London, SW1E 5DH, UK
Tel: +44 (0)7857 796 052, +44 (0)20 7045 4114

Navigator Gas Investor Relations
Email: [email protected], [email protected]
333 Clay Street, Suite 2400, Houston, Texas, U.S.A. 77002
Tel: +1 713 373 6197, +44 (0)20 7340 4850

Investor Relations / Media Advisors
Nicolas Bornozis / Paul Lampoutis
Capital Link – New York
Tel: +1-212-661-7566
Email: [email protected]   

Category: Financial



Posted on

Sun Life announces Annual Meetings of shareholders and voting policyholders and availability of 2024 Annual Report, 2025 Management Information Circular and 2025 Information for Voting Policyholders’ Booklet

PR Newswire


TORONTO
, March 25, 2025 /PRNewswire/ – Sun Life Financial Inc. (TSX: SLF) (NYSE: SLF) (the “Company”) today announced that its Annual Meeting of shareholders and the Annual Meeting of voting policyholders of Sun Life Assurance Company of Canada scheduled for Thursday, May 8, 2025 will be held both via live webcast and in person. The Company also announced that its 2024 Annual Report and its Notice of Annual Meeting and Management Information Circular for the 2025 annual meeting are now available.

Annual Meetings of Shareholders and Voting Policyholders
Shareholders and voting policyholders will have the opportunity to attend the meeting in person, at the address set out below, or virtually from any location. They will have the opportunity to ask questions and vote on a number of important matters regardless of whether they attend the meeting in person or virtually.

Shareholders and voting policyholders are advised to periodically check the Annual Meetings page on sunlife.com in advance of the meeting for updated information.


Date:                                           

Thursday, May 8, 2025


Time:                                           

5 p.m. (Toronto time)


Online:                                       



meetings.lumiconnect.com/400-542-265-283

Password: sunlife2025 (case sensitive)


In Person:                                   

1 York Street, 35th floor

Toronto, Ontario

For detailed instructions on how to join the webcast and vote at the virtual meeting, shareholders should refer to the 2025 Management Information Circular and voting policyholders should refer to the 2025 Information for Voting Policyholders’ Booklet and their proxy form or voting instruction form.

Shareholders and voting policyholders are encouraged to vote in advance by one of the methods described in the 2025 Management Information Circular or 2025 Information for Voting Policyholders’ Booklet, as applicable, by Tuesday, May 6, 2025 at 5 p.m. (Toronto time). 

If you have any questions, please call our transfer agent, TSX Trust Company at the following numbers:

Canada and the United States:

1-877-224-1760

United Kingdom, Republic of Ireland, Channel Islands and Isle of Man:

+ 44 (0) 345-602-1587

Philippines:

632-5318-8567 (Metro Manila)

1-800-1-888-2422 (Provinces)

Hong Kong:

852-2862-8555

Other countries:

1-416-682-3865

At the conclusion of the Annual Meeting, M. Marianne Harris, Corporate Director, will retire from the Board of Directors.

Meeting Materials
The meeting materials for Sun Life Financial Inc. have been filed with the Canadian securities regulators and the United States Securities and Exchange Commission. Distribution to shareholders began today and materials can also be accessed electronically on:
SEDAR+ at https://www.sedarplus.ca
EDGAR at www.sec.gov/edgar 
Our transfer agent’s website at www.meetingdocuments.com/TSXT/slf
Our website at sunlife.com/2025agm and sunlife.com/AnnualReport

Shareholders may obtain printed copies of the audited annual financial statements free of charge by contacting the Company through its website.

The meeting materials for Sun Life Assurance Company of Canada will begin to be distributed to voting policyholders on March 31, 2025 and can be accessed electronically from March 31, 2025 on:
Our transfer agent’s website at https://www.meetingdocuments.com/TSXT/sla/
Our website at sunlife.com/2025agm

2024 Annual Report
The 2024 Annual Report includes the Company’s management’s discussion and analysis, consolidated financial statements, earnings by business group and other Company information.

Our report features cover artwork by Cheryl R. Riley, an American artist whose work explores important themes of connection and resilience. Her creative vision defined by care, authenticity, inspiration, boldness, and impact elevates our Annual Report cover and embodies Sun Life’s Purpose of helping Clients achieve lifetime financial security and live healthier lives.

About Sun Life

Sun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of December 31, 2024, Sun Life had total assets under management of $1.54 trillion. For more information, please visit sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF.

Note to editors: All figures in Canadian dollars

To contact Sun Life media relations, please email

[email protected]

To contact Sun Life investor relations, please email

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sun-life-announces-annual-meetings-of-shareholders-and-voting-policyholders-and-availability-of-2024-annual-report-2025-management-information-circular-and-2025-information-for-voting-policyholders-booklet-302411315.html

SOURCE Sun Life Financial Inc.

Posted on

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

PR Newswire

Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models

Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations

LAUSANNE, Switzerland, March 25, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.

“We are excited to present preclinical data on our exatecan-based Claudin-6, PSMA, and ACST2-targeting antibody-drug conjugates,” said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. “These ADCs hold promise for targeted cancer treatment in a broad range of cancer types, and we are pleased to have the opportunity to share our learnings across select solid tumors where there remains unmet need.”

Details of ADC Therapeutics’ oral presentation at AACR are as follows:

Title: Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models
Abstract: 1163
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutic Agents
Date and Time: Sunday, April 27, 2025, 3:00-5:00 p.m. CT
Presenter: Chris Pickford, Head of Clinical Research, ADC Therapeutics

Details of ADC Therapeutics’ poster presentations at AACR are as follows:

Title: Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer
Abstract: 6736
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 4
Date and Time: Wednesday, April 30, 2025, 9:00 a.m. – 12:00 p.m. CT
Presenter: Ben Leatherdale, Senior Scientist, ADC Therapeutics

Title: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers
Abstract: 1580
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 1
Date and Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CT
Presenter: Danilo Cucchi, Senior Scientist, ADC Therapeutics

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing and future results of the Company’s early research in exatecan-based Claudin-6, PSMA and ASCT2-targeting antibody-drug conjugates; the expected cash runway into mid-2026 the Company’s ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s or its partners’ research and development projects or clinical trials including LOTIS 5 and 7 and ADCT 602; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors

Marcy Graham

ADC Therapeutics
[email protected]
+1 650-667-6450

Media

Nicole Riley

ADC Therapeutics
[email protected]
+1 862-926-9040

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2025-302411310.html

SOURCE ADC Therapeutics SA

Posted on

EPSIUM ENTERPRISE LIMITED Announces Pricing of US$5.0 Million Initial Public Offering

PR Newswire


MACAU
, March 25, 2025 /PRNewswire/ — EPSIUM ENTERPRISE LIMITED (the “Company” or “EPSIUM”), a company engaged in importing and wholesaling primarily alcoholic beverages in Macau, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares at a public offering price of US$4.00 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on March 26, 2025 under the ticker symbol “EPSM.”

The Company expects to receive aggregate gross proceeds of US$5.0 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about March 27, 2025, subject to the satisfaction of customary closing conditions.

Net proceeds from the Offering will be used for (i) approximately 10% of the net proceeds for sales and product innovation and brand building, (ii) approximately 60% of the net proceeds for the acquisition of, or investment in, assets, technologies, solutions, or businesses that complement our business, (iii) approximately 20% of the net proceeds for general corporate purposes, and (iv) approximately 10% of the net proceeds for reserve and subject to the discretion of the board of directors.

The Offering is being conducted on a firm commitment basis. D. Boral Capital LLC is acting as the sole underwriter for the Offering. iTKG Law LLC is acting as U.S. securities counsel to the Company, and Schlueter & Associates, P.C. is acting as U.S. counsel to the underwriter in connection with the Offering.

A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) (File Number: 333-276313) and was declared effective by the SEC on March 25, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the prospectus relating to the Offering may be obtained from D. Boral Capital LLC, Attn: 590 Madison Avenue 39th Floor, New York, NY 10022, or by email at [email protected], or by telephone at +1(212)-970-5150. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About EPSIUM ENTERPRISE LIMITED

Through its Macau operating entity, Companhia de Comercio Luz Limitada (“Luz”), a limited liability company organized under Macau laws in 2010, EPSIUM is engaged in importing and wholesaling primarily alcoholic beverages in Macau. Through Luz, the Company imports and sells a broad range of premium beverages, primarily alcoholic beverages and, in 2022, a small quantity of tea and fruit juice. The alcoholic beverages the Company sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol. Sales of Chinese liquor is by far the Company’s most significant operations, and the Company is a top wholesaler of high-end Chinese liquor in Macau. For more information, please visit the Company’s website: www.epsium-group.com. 

Forward-Looking Statements

Certain statements in this press release are forward-looking statements, including, but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the Registration Statement filed with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:

EPSIUM ENTERPRISE LIMITED
Investor Relations Department
Email: [email protected] 

Cision View original content:https://www.prnewswire.com/news-releases/epsium-enterprise-limited-announces-pricing-of-us5-0-million-initial-public-offering-302411309.html

SOURCE Epsium Enterprise Limited

Posted on

HII’s Ingalls Shipbuilding Launches Guided Missile Destroyer Future USS Jeremiah Denton (DDG 129)

PASCAGOULA, Miss., March 25, 2025 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division successfully launched future USS Jeremiah Denton (DDG 129) today, the third Flight III Arleigh Burke-class destroyer to be built at the shipyard.

Shipbuilders transferred DDG 129 from land to the company’s dry dock using translation railcars to support the ship during the move. Once in the dry dock, the ship was floated and moved by tugboats to a pier at the shipyard.

“The launch of DDG 129 is a testament to the hard work and dedication of our Ingalls shipbuilders and a collaborative achievement with our Navy partners,” Ingalls Shipbuilding DDG Program Manager Ben Barnett said. “The future USS Jeremiah Denton will now undergo final outfitting, systems activation, and testing before entering the fleet.”

DDG 129 is named for former U.S. Sen. Jeremiah Denton Jr., a Vietnam War veteran who was awarded the Navy Cross for his heroism as a prisoner of war. Following his Navy career, he was elected to the U.S. Senate representing his home state of Alabama in 1980.


Photos accompanying this release are available at: http://hii.com/news/hiis-ingalls-shipbuilding-launches-guided-missile-destroyer-future-uss-jeremiah-denton-ddg-129/.

An Arleigh Burke-class Flight III destroyer features the AN/SPY-6(V)1 Air and Missile Defense Radar (AMDR) and the Aegis Baseline 10 Combat System that is required to keep pace with the threats well into the 21st century. Ingalls Shipbuilding has five Flight IIIs currently under construction including Ted Stevens (DDG 128), Jeremiah Denton (DDG 129), George M. Neal (DDG 131), Sam Nunn (DDG 133) and Thad Cochran (DDG 135).

About HII

HII is a global, all-domain defense provider. HII’s mission is to deliver the world’s most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world.

As the nation’s largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII’s workforce is 44,000 strong. For more information, visit:

Contact:

Kimberly K. Aguillard
228-355-5663
[email protected]

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9e8e79ba-a38b-49f6-9987-fc22052481dd